2,423 Shares in Medtronic plc (NYSE:MDT) Purchased by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC acquired a new stake in Medtronic plc (NYSE:MDT) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,423 shares of the medical technology company’s stock, valued at approximately $224,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fortitude Family Office LLC acquired a new stake in shares of Medtronic in the third quarter valued at approximately $27,000. Lynx Investment Advisory acquired a new stake in shares of Medtronic in the 2nd quarter valued at $28,000. Gleason Group Inc. bought a new stake in shares of Medtronic during the second quarter worth $42,000. Opal Wealth Advisors LLC acquired a new position in shares of Medtronic during the second quarter valued at $43,000. Finally, Olistico Wealth LLC bought a new position in Medtronic in the second quarter valued at about $45,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 1.4 %

NYSE:MDT opened at $89.25 on Friday. The company has a market cap of $114.45 billion, a PE ratio of 30.15, a PEG ratio of 2.60 and a beta of 0.84. The stock has a 50-day simple moving average of $89.61 and a 200 day simple moving average of $84.06. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.61 and a current ratio of 2.13. Medtronic plc has a 52-week low of $69.32 and a 52-week high of $92.68.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The business had revenue of $7.97 billion during the quarter, compared to the consensus estimate of $7.90 billion. During the same quarter last year, the firm earned $1.20 earnings per share. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. On average, sell-side analysts expect that Medtronic plc will post 5.44 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 11th. Investors of record on Friday, September 27th were issued a dividend of $0.70 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $2.80 annualized dividend and a yield of 3.14%. Medtronic’s payout ratio is presently 94.59%.

Analyst Ratings Changes

Several analysts have weighed in on the company. UBS Group raised Medtronic from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $76.00 to $90.00 in a report on Thursday, August 15th. Wells Fargo & Company raised their price objective on shares of Medtronic from $105.00 to $106.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Daiwa America upgraded shares of Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Friday, October 25th. Finally, Robert W. Baird upped their price objective on Medtronic from $82.00 to $90.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $95.36.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.